[
  {
    "ts": null,
    "headline": "Goldman Sachs Maintains Merck (MRK) Buy Recommendation",
    "summary": "Goldman Sachs Maintains Merck (MRK) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=a3d9ca9157b5d574292c52f8f63960e80a16fa95ca430a97eb19f1243d110276",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764708330,
      "headline": "Goldman Sachs Maintains Merck (MRK) Buy Recommendation",
      "id": 137664837,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a3d9ca9157b5d574292c52f8f63960e80a16fa95ca430a97eb19f1243d110276"
    }
  },
  {
    "ts": null,
    "headline": "Retiring On Dividends: SCHD Vs. Covered Call ETFs",
    "summary": "Compare SCHD and covered call ETFs like JEPI for retirement income. Read about which passive income strategy best funds your retirement goals.",
    "url": "https://finnhub.io/api/news?id=7bc44d4c484196bf9999683817fa3de9c53ff6918b0f9411feb48d02865b0202",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764684031,
      "headline": "Retiring On Dividends: SCHD Vs. Covered Call ETFs",
      "id": 137664425,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2210232423/image_2210232423.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Compare SCHD and covered call ETFs like JEPI for retirement income. Read about which passive income strategy best funds your retirement goals.",
      "url": "https://finnhub.io/api/news?id=7bc44d4c484196bf9999683817fa3de9c53ff6918b0f9411feb48d02865b0202"
    }
  },
  {
    "ts": null,
    "headline": "Vaccine stocks brace for shock waves at this week’s ACIP meeting",
    "summary": "Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.",
    "url": "https://finnhub.io/api/news?id=9df4e5df0f6ad295e04cf666ad129b80b9c1de065ee2482c4456ccb42e98f79e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764681144,
      "headline": "Vaccine stocks brace for shock waves at this week’s ACIP meeting",
      "id": 137662243,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.",
      "url": "https://finnhub.io/api/news?id=9df4e5df0f6ad295e04cf666ad129b80b9c1de065ee2482c4456ccb42e98f79e"
    }
  },
  {
    "ts": null,
    "headline": "Has Merck’s Valuation Shifted After Key Pipeline Updates and an 18% Stock Jump?",
    "summary": "Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% over the last 30 days, even though it’s dipped 3.6% over the last week. This shows just how quickly market sentiment can shift. This recent volatility comes as investors react to a wave of positive pipeline updates and strategic partnership announcements, which have fueled fresh optimism about...",
    "url": "https://finnhub.io/api/news?id=dff66553245d901cffbd247808ad82359501ae1c68f97dfa1df7069d04593fe2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764677677,
      "headline": "Has Merck’s Valuation Shifted After Key Pipeline Updates and an 18% Stock Jump?",
      "id": 137662244,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% over the last 30 days, even though it’s dipped 3.6% over the last week. This shows just how quickly market sentiment can shift. This recent volatility comes as investors react to a wave of positive pipeline updates and strategic partnership announcements, which have fueled fresh optimism about...",
      "url": "https://finnhub.io/api/news?id=dff66553245d901cffbd247808ad82359501ae1c68f97dfa1df7069d04593fe2"
    }
  },
  {
    "ts": null,
    "headline": "Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy",
    "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (",
    "url": "https://finnhub.io/api/news?id=4bdade1aaa9ba0b8518fbae65b163b9cdc047a136dd12174cadafa6f75ed8a4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764666000,
      "headline": "Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy",
      "id": 137662245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (",
      "url": "https://finnhub.io/api/news?id=4bdade1aaa9ba0b8518fbae65b163b9cdc047a136dd12174cadafa6f75ed8a4f"
    }
  },
  {
    "ts": null,
    "headline": "1 Value Stock to Target This Week and 2 We Question",
    "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
    "url": "https://finnhub.io/api/news?id=c694b768e63b69fcb85ad277d945c8fca27c9f3c962f50049bb02ee5b3f67bed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764650247,
      "headline": "1 Value Stock to Target This Week and 2 We Question",
      "id": 137662246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
      "url": "https://finnhub.io/api/news?id=c694b768e63b69fcb85ad277d945c8fca27c9f3c962f50049bb02ee5b3f67bed"
    }
  }
]